1. Inicio
  2. Publicaciones
  3. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57).

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57).

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Podzamczer D
  • Micán R
  • Tiraboschi J
  • Portilla J
  • Domingo P
  • Llibre JM
  • Ribera E
  • Vivancos MJ
  • Morano L
  • Masiá M
  • Gómez C
  • Fanjul F
  • Payeras A
  • Inciarte A
  • Estrada V
  • Rivero A
  • Castro Á
  • Bernal E
  • Vinuesa D
  • Knobel H
  • Troya J
  • Macías J
  • Sanz J
  • Navarro-Alcaraz A
  • Caicedo A
  • Fernández G
  • Martínez E
  • Moreno S

Grupos

Abstract

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is the reference for combination therapy based on protease inhibitors due to its efficacy, tolerability, and convenience. Head-to-head randomized comparisons between D/C/F/TAF and combination therapy based on integrase inhibitors in antiretroviral-naive patients are lacking.

© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Datos de la publicación

ISSN/ISSNe:
2328-8957, 2328-8957

Open Forum Infectious Diseases  OXFORD UNIV PRESS INC

Tipo:
Article
Páginas:
-
PubMed:
35237700
Factor de Impacto:
1,317 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 6

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • darunavir/cobicistat, dolutegravir, naive patients, tenofovir alafenamide, virologic efficacy

Cita

Compartir